Joseph Laplume Sells 400 Shares of Charles River Laboratories International (NYSE:CRL) Stock

Charles River Laboratories International, Inc. (NYSE:CRL) EVP Joseph Laplume sold 400 shares of Charles River Laboratories International stock in a transaction on Friday, August 22nd. The shares were sold at an average price of $163.72, for a total transaction of $65,488.00. Following the completion of the transaction, the executive vice president owned 23,716 shares in the company, valued at approximately $3,882,783.52. This trade represents a 1.66% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Charles River Laboratories International Price Performance

Shares of CRL traded up $0.49 during mid-day trading on Tuesday, hitting $220.19. The company’s stock had a trading volume of 42,146 shares, compared to its average volume of 765,870. The firm has a 50-day simple moving average of $192.82 and a 200 day simple moving average of $174.70. The firm has a market capitalization of $10.84 billion, a P/E ratio of -140.90, a P/E/G ratio of 6.57 and a beta of 1.61. The company has a current ratio of 1.37, a quick ratio of 1.10 and a debt-to-equity ratio of 0.64. Charles River Laboratories International, Inc. has a 1-year low of $91.86 and a 1-year high of $228.88.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings data on Wednesday, November 5th. The medical research company reported $2.43 EPS for the quarter, beating the consensus estimate of $2.32 by $0.11. The firm had revenue of $1 billion during the quarter, compared to analysts’ expectations of $990.43 million. Charles River Laboratories International had a negative net margin of 2.07% and a positive return on equity of 15.78%. The business’s revenue for the quarter was down .5% compared to the same quarter last year. During the same quarter last year, the business earned $2.59 earnings per share. Analysts predict that Charles River Laboratories International, Inc. will post 9.36 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on CRL shares. Wall Street Zen raised shares of Charles River Laboratories International from a “hold” rating to a “buy” rating in a research report on Sunday, December 21st. Argus set a $200.00 price objective on shares of Charles River Laboratories International in a research report on Monday, November 17th. William Blair raised shares of Charles River Laboratories International from a “market perform” rating to an “outperform” rating in a research note on Monday, October 6th. Morgan Stanley set a $185.00 price target on shares of Charles River Laboratories International in a research report on Monday, December 1st. Finally, Mizuho set a $215.00 price objective on Charles River Laboratories International in a research report on Friday, January 9th. One research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $209.46.

Institutional Investors Weigh In On Charles River Laboratories International

A number of hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. boosted its holdings in shares of Charles River Laboratories International by 0.5% in the third quarter. Vanguard Group Inc. now owns 5,839,743 shares of the medical research company’s stock valued at $913,686,000 after acquiring an additional 27,989 shares in the last quarter. Allspring Global Investments Holdings LLC grew its holdings in shares of Charles River Laboratories International by 29.1% during the 2nd quarter. Allspring Global Investments Holdings LLC now owns 2,291,126 shares of the medical research company’s stock valued at $353,750,000 after acquiring an additional 516,521 shares in the last quarter. Ariel Investments LLC increased its holdings in Charles River Laboratories International by 28.6% in the second quarter. Ariel Investments LLC now owns 1,415,348 shares of the medical research company’s stock worth $214,751,000 after buying an additional 314,572 shares during the last quarter. Invesco Ltd. raised its holdings in shares of Charles River Laboratories International by 1.0% during the 3rd quarter. Invesco Ltd. now owns 1,249,178 shares of the medical research company’s stock valued at $195,446,000 after purchasing an additional 12,035 shares in the last quarter. Finally, Bank of America Corp DE lifted its position in shares of Charles River Laboratories International by 13.4% in the third quarter. Bank of America Corp DE now owns 1,163,348 shares of the medical research company’s stock worth $182,017,000 after buying an additional 137,335 shares during the last quarter. Institutional investors own 98.91% of the company’s stock.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.